Seek Returns

BNTX vs. PCVX: BioNTech vs. Vaxcyte Stock Comparison

How do BioNTech (BNTX) and Vaxcyte (PCVX) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

BioNTech (BNTX) and Vaxcyte (PCVX) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.

Vaxcyte (PCVX) trades as ordinary local shares, while BioNTech (BNTX) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Company profile comparison for BioNTech (BNTX) and Vaxcyte (PCVX)
Profile ItemBNTXPCVX
NameBioNTech SE American Depositary ShareVaxcyte Inc.
Country/RegionGermanyUnited States
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnologyBiotechnology
GICS Sub-IndustryBiotechnologyBiotechnology
Market Capitalization21.70 billion USD10.11 billion USD
CurrencyUSDUSD
ExchangeNasdaqNasdaq
Listing DateOctober 10, 2019June 12, 2020
Security TypeADRCommon Stock

Price Performance

Cumulative Growth

BNTX
PCVX
GSPC
Loading price history…
BioNTech (BNTX) vs. Vaxcyte (PCVX), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for BioNTech (BNTX) and Vaxcyte (PCVX). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for BioNTech (BNTX) and Vaxcyte (PCVX). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for BioNTech (BNTX) and Vaxcyte (PCVX)
MetricBNTXPCVX
Total Return (1Y)-14.78%59.00%
Total Return (3Y, Annualized)-3.99%11.29%
Total Return (5Y, Annualized)-17.02%21.60%

Risk Profile

Drawdown History

BNTX
PCVX
GSPC
Loading price history…
BioNTech (BNTX) vs. Vaxcyte (PCVX), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for BioNTech (BNTX) and Vaxcyte (PCVX). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for BioNTech (BNTX) and Vaxcyte (PCVX)
MetricBNTXPCVX
Volatility (1Y, Annualized)47.44%56.01%
Beta (5Y)1.301.26
Max Drawdown (5Y)-78.10%-76.22%
Avg. Volume (3M)1.21M2.12M

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
BNTX and PCVX are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for BioNTech (BNTX) and Vaxcyte (PCVX)
MetricBNTXPCVX
Sharpe Ratio (1Y)-0.400.98
Sortino Ratio (1Y)-0.591.76

Profitability

ROE (TTM)

Both BioNTech (BNTX) at -8.14% and Vaxcyte (PCVX) at -42.68% report negative ROE values. Negative ROE can reflect losses or negative shareholders’ equity, so both readings need extra context.

BNTX

Pharmaceuticals, Biotechnology & Life Sciences industry group

-8.14%

Max
109.18%
Q3
6.23%
BNTX
-8.14%
Median
-26.66%
Q1
-64.05%
Min
-167.77%

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

-42.68%

Max
109.18%
Q3
6.23%
Median
-26.66%
PCVX
-42.68%
Q1
-64.05%
Min
-167.77%
Loading chart…
BioNTech (BNTX) vs. Vaxcyte (PCVX): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

BioNTech (BNTX) reports a negative net margin of -60.87%, usually indicating a net loss over the period. Meanwhile Vaxcyte (PCVX) reports 0.00%, ranking against industry peers normally.

BNTX

Pharmaceuticals, Biotechnology & Life Sciences industry group

-60.87%

Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%
BNTX
-60.87%

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

Max
18.05%
Q3
4.78%
PCVX
0.00%
Median
0.00%
Q1
-4.14%
Min
-17.05%
Loading chart…
BioNTech (BNTX) vs. Vaxcyte (PCVX): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

BioNTech (BNTX) at 30.28% operates in the top operating margin quartile, ahead of Vaxcyte (PCVX) at 0.00%, which runs around its industry’s norm.

BNTX

Pharmaceuticals, Biotechnology & Life Sciences industry group

30.28%

Max
83.12%
BNTX
30.28%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

Max
83.12%
Q3
14.77%
PCVX
0.00%
Median
0.00%
Q1
-78.82%
Min
-207.40%
Loading chart…
BioNTech (BNTX) vs. Vaxcyte (PCVX): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for BioNTech (BNTX) and Vaxcyte (PCVX)
MetricBNTXPCVX
ROE (TTM)-8.14%-42.68%
ROA (TTM)-4.04%-24.98%
Net Margin (TTM)-60.87%0.00%
Operating Margin (TTM)30.28%0.00%
Gross Margin (TTM)76.73%0.00%

Growth

Revenue Growth

Only one side can be read here: BioNTech (BNTX) reports revenue growth of 4.32%, ranked against its industry; Vaxcyte (PCVX) has no revenue growth figure this period.

Loading chart…
BioNTech (BNTX) vs. Vaxcyte (PCVX): A comparison of their Revenue Growth across different time periods.

EPS Growth

Neither BioNTech (BNTX) nor Vaxcyte (PCVX) reports a EPS growth value for this period, so a direct comparison isn't possible.

Growth Metrics

Growth metrics for BioNTech (BNTX) and Vaxcyte (PCVX)
MetricBNTXPCVX
Revenue Growth (YoY)4.32%--
Revenue Growth (3Y CAGR)-45.06%--
EPS Growth (YoY)----
EPS Growth (3Y CAGR)----

Financial Strength

Current Ratio (MRQ)

Both BioNTech (BNTX) at 8.55 and Vaxcyte (PCVX) at 4.56 carry current ratio within their industries’ typical mid-ranges, suggesting balanced short-term liquidity relative to peers.

BNTX

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.55

Max
25.13
Q3
12.13
BNTX
8.55
Median
5.52
Q1
2.47
Min
0.10

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.56

Max
25.13
Q3
12.13
Median
5.52
PCVX
4.56
Q1
2.47
Min
0.10
Loading chart…
BioNTech (BNTX) vs. Vaxcyte (PCVX): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

BioNTech (BNTX) at 0.02 keeps leverage in the lower industry quartile, while Vaxcyte (PCVX) at 0.09 runs a more typical debt-to-equity mix.

BNTX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.02

Max
1.42
Q3
0.65
Median
0.15
Q1
0.02
BNTX
0.02
Min
0.00

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.09

Max
1.42
Q3
0.65
Median
0.15
PCVX
0.09
Q1
0.02
Min
0.00
Loading chart…
BioNTech (BNTX) vs. Vaxcyte (PCVX): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for BioNTech (BNTX) and Vaxcyte (PCVX)
MetricBNTXPCVX
Current Ratio (MRQ)8.554.56
Debt / Equity (MRQ)0.020.09
Net Debt / EBITDA----

Dividends

Dividend Yield (TTM)

Neither BioNTech (BNTX) nor Vaxcyte (PCVX) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

BNTX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

BNTX
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

PCVX
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
BioNTech (BNTX) vs. Vaxcyte (PCVX): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Neither BioNTech (BNTX) nor Vaxcyte (PCVX) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

BNTX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

BNTX
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

PCVX
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
BioNTech (BNTX) vs. Vaxcyte (PCVX): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for BioNTech (BNTX) and Vaxcyte (PCVX)
MetricBNTXPCVX
Dividend Yield (TTM)0.00%0.00%
Dividend Payout Ratio (TTM)0.00%0.00%

Valuation

P/E Ratio (TTM)

Neither BioNTech (BNTX) nor Vaxcyte (PCVX) reports a P/E ratio value for this period, so a direct comparison isn’t possible.

BNTX

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
85.34
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07
BNTX
--

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
85.34
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07
PCVX
--
Loading chart…
BioNTech (BNTX) vs. Vaxcyte (PCVX): Neither stock reports P/E ratio, so the chart shows available benchmark boxes without value markers.

P/S Ratio (TTM)

A sales-based read is only available for BioNTech (BNTX), whose P/S ratio of 8.96 ranks against industry peers; Vaxcyte (PCVX) reports no figure this period.

BNTX

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.96

Max
58.18
Q3
25.77
BNTX
8.96
Median
7.30
Q1
3.01
Min
0.01

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
58.18
Q3
25.77
Median
7.30
Q1
3.01
Min
0.01
PCVX
--
Loading chart…
BioNTech (BNTX) vs. Vaxcyte (PCVX): PCVX does not report P/S ratio, so it has no value marker; BNTX is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

P/B Ratio (MRQ)

BioNTech (BNTX) at 1.09 sits in the lower P/B ratio quartile against book while Vaxcyte (PCVX) at 3.83 is valued near its industry’s middle — BNTX is cheaper on assets, though weigh it against ROE and asset quality.

BNTX

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.09

Max
13.53
Q3
6.54
Median
3.25
Q1
1.69
BNTX
1.09
Min
-5.59

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.83

Max
13.53
Q3
6.54
PCVX
3.83
Median
3.25
Q1
1.69
Min
-5.59
Loading chart…
BioNTech (BNTX) vs. Vaxcyte (PCVX): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for BioNTech (BNTX) and Vaxcyte (PCVX)
MetricBNTXPCVX
P/E Ratio (TTM)----
P/S Ratio (TTM)8.96--
P/B Ratio (MRQ)1.093.83
Free Cash Flow Yield (TTM)-7.34%-5.24%